Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis

New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature

(2016) D. Roccatello et al.   AUTOIMMUNITY REVIEWS

Assessment of the Effects of Rituximab Monotherapy on Different Subsets of Circulating T-Regulatory Cells and Clinical Disease Severity in Severe Pemphigus Vulgaris

(2016) Rajsmita Bhattacharjee et al.   DERMATOLOGY

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

(2014) D. Gomez-Almaguer et al.   BLOOD

Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

(2014) M. Khellaf et al.   BLOOD

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

(2014) J. B. Bussel et al.   HAEMATOLOGICA

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

(2013) S. Gudbrandsdottir et al.   BLOOD

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia

(2010) Zhenyu Li et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

The ITP syndrome: pathogenic and clinical diversity

(2009) D. B. Cines et al.   BLOOD

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

(2008) R. Stasi et al.   BLOOD

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura

(2008) J. Yu et al.   BLOOD

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

(2008) B. Godeau et al.   BLOOD